Establishing a model spinal cord injury in the African green monkey for the preclinical evaluation of biodegradable polymer scaffolds seeded with human neural stem cells. Download PDF
The use of biomaterials for transplantation and directed differentiation of nerve progenitor cells for central nervous system repair. Download PDF
InVivo scientists engineer a drug delivery and tissue engineering method to increase survival of neural stem cells after transplantation into the injured spinal cord. Download PDF
Design and Fabrication of biocompatible polymer implants suitable for neural tissue engineering, drug delivery and prosthetics. Download PDF
Functional recovery following spinal cord injury mediated by novel polymer scaffolds that can be used alone and/or as carriers to administer human neural stem cells. Download PDF
InVivo Therapeutics is focused on utilizing polymers as a platform technology to develop and commercialize groundbreaking treatments for spinal cord injuries (SCI). InVivo’s technologies encompasses multiple strategies involving biomaterials, U.S. Food & Drug Administration (FDA) approved drugs, growth factors, and human neural stem cells (hNSCs).
We intend to leverage our platform technology to deliver several products to the market including:
A biocompatible polymer scaffolding device
to treat acute SCI
A biocompatible hydrogel for local controlled release
of methylprednisolone to treat acute SCI
A biocompatible polymer scaffolding device seeded with
autologous hNSCs to treat acute and chronic SCI
InVivo’s proprietary technology was co-invented by Robert S. Langer, ScD, the David H. Koch Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, affiliated with Massachusetts General Hospital. The patent rights that are the basis for InVivo’s products are under an exclusive, worldwide license from Children’s Medical Center Corporation and Massachusetts Institute of Technology.
Data on InVivo’s technology was first published in PNAS in 2002 and has since been demonstrated to successfully promote functional recovery following traumatic spinal cord injury in several models including rodent and non-human primate models. Data from InVivo’s pilot non-human primate study was published in the Journal of Neuroscience Methods in 2010.
View Videos About Our Technology
InVivo Therapeutics’ Implanted Scaffold Technology for Penetrating Injury
InVivo Therapeutics’ Hydrogel Technology
InVivo Therapeutics’ Injectable Scaffold Treatment for Contusion Spinal Cord Injury
Dr. Robert Langer Sc.D on InVivo Therapeutics’ scaffolding technology
Dr. Jonathan Slotkin M.D. on InVivo Therapeutics’ treatment platform
Dr. W. Dalton Deitrich III, Ph.D discusses InVivo Therapeutics’ Scaffolding & Schwan Cells